biote Corp
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
BTMD$1.11+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| September 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $38,225 | $89,002 |
| Accounts receivable, net | 8,493 | 6,809 |
| Inventory, net | 16,200 | 17,307 |
| Other current assets | 7,065 | 9,225 |
| Total current assets | 69,983 | 122,343 |
| Property and equipment, net | 5,813 | 1,218 |
| Capitalized software, net | 4,974 | 4,973 |
| Goodwill | 5,516 | — |
| Intangible assets, net | 5,666 | — |
| Operating lease right-of-use assets | 3,376 | 1,877 |
| Deferred tax asset | 5,924 | 24,884 |
| Total assets | $101,252 | $155,295 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $4,374 | $4,155 |
| Accrued expenses | 8,185 | 8,497 |
| Term loan, current | 6,250 | 6,250 |
| Deferred revenue, current | 2,927 | 3,002 |
| Earnout liabilities, current | 100 | — |
| Operating lease liabilities, current | 482 | 311 |
| Share repurchase liabilities, current | 24,192 | — |
| Total current liabilities | 46,510 | 22,215 |
| Term loan, net of current portion | 102,548 | 106,630 |
| Revolving loans | 10,000 | — |
| Deferred revenue, net of current portion | 1,603 | 1,322 |
| Operating lease liabilities, net of current portion | 3,026 | 1,680 |
| Share repurchase liabilities, net of current portion | 43,610 | — |
| TRA liability | 4,424 | 18,894 |
| Earnout liabilities, net of current portion | 16,355 | 41,100 |
| Total liabilities | 228,076 | 191,841 |
| Commitments and contingencies (See Note 19) | ||
| Stockholders’ Deficit | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued or outstanding as of September 30, 2024 and December 31, 2023 | — | — |
| Class A common stock, $0.0001 par value, 600,000,000 shares authorized; 32,700,163 and 35,842,383, shares issued, 31,112,663 and 34,254,883 shares outstanding as of September 30, 2024 and December 31, 2023, respectively | 3 | 3 |
| Class V voting stock, $0.0001 par value, 100,000,000 shares authorized; 7,249,879 and 38,819,066 shares issued, 5,221,653 and 28,819,066 shares outstanding as of September 30, 2024 and December 31, 2023, respectively | 1 | 3 |
| Additional paid-in capital | — | — |
| Accumulated deficit | (124,717) | (29,391) |
| Accumulated other comprehensive loss | (29) | (12) |
| Treasury stock, at cost | (5,600) | — |
| biote Corp.’s stockholders’ deficit | (130,342) | (29,397) |
| Noncontrolling interest | 3,518 | (7,149) |
| Total stockholders’ deficit | (126,824) | (36,546) |
| Total liabilities and stockholders’ deficit | $101,252 | $155,295 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.